Cathelicidin-deficient mice exhibit increased survival and upregulation of key inflammatory response genes following cecal ligation and puncture

Imagem de Miniatura
Arquivos
art_SEVERINO_Cathelicidindeficient_mice_exhibit_increased_survival_and_upregulation_of_2017.PDF (806.77 KB)
Citações na Scopus
17
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Autores
SEVERINO, Patricia
SILVA, Elisangela de Paula
NIZET, Victor
Citação
JOURNAL OF MOLECULAR MEDICINE-JMM, v.95, n.9, p.995-1003, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Antimicrobial peptides possess a myriad of molecular properties including bacterial killing and the regulation of many aspects of innate immunity. Cathelicidins are a group of antimicrobial peptides widely investigated by the scientific community. Many studies have focused on the bactericidal and pro-inflammatory roles of cathelicidins. Because the role of endogenous cathelicidin expression remains obscure in deep-seated systemic infections, we induced sepsis in cathelicidin knockout and wild-type (WT) mice by cecal ligation and puncture, performing transcriptome screening by DNA micro-array in conjunction with other immunologic assays. Cathelicidin-deficient mice showed increased survival compared to WT mice in this established experimental model of polymicrobial sepsis, in association with upregulation of certain key inflammatory response genes. Therefore, cathelicidins can exert both pro- and anti-inflammatory activities depending on the disease and cellular context.
Palavras-chave
Sepsis, Cathelicidin, Inflammation, Gene expression
URI
https://observatorio.fm.usp.br/handle/OPI/21778
Referências
  1. Audrain B, 2013, APPL ENVIRON MICROB, V79, P7770, DOI 10.1128/AEM.02593-13
  2. Barbeiro DF, 2013, MICROBES INFECT, V15, P342, DOI 10.1016/j.micinf.2013.01.001
  3. Beaumont PE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099029
  4. Chromek M, 2006, NAT MED, V12, P636, DOI 10.1038/nm1407
  5. Chromek M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046476
  6. Ciornei CD, 2005, ANTIMICROB AGENTS CH, V49, P2845, DOI 10.1128/AAC.49.7.2845-2850.2005
  7. Cirioni O, 2006, ANTIMICROB AGENTS CH, V50, P1672, DOI 10.1128/AAC.50.5.1672-1679.2006
  8. Coffelt SB, 2009, MOL CANCER RES, V7, P907, DOI 10.1158/1541-7786.MCR-08-0326
  9. Cole JN, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.VMBF-0006-2015
  10. Coorens M, 2017, SCI REP-UK, V7, DOI 10.1038/srep40874
  11. da Silva FP, 2017, IMMUNOL LETT, V182, P57, DOI 10.1016/j.imlet.2017.01.004
  12. da Silva FP, 2013, TISSUE CELL, V45, P318, DOI 10.1016/j.tice.2013.04.003
  13. da Silva FP, 2012, PEPTIDES, V36, P308, DOI 10.1016/j.peptides.2012.05.014
  14. da Silva FP, 2009, IMMUNOL CELL BIOL, V87, P496, DOI 10.1038/icb.2009.19
  15. Danka ES, 2015, J INFECT DIS, V211, P1164, DOI 10.1093/infdis/jiu577
  16. Devitt A, 1998, NATURE, V392, P505
  17. Durr UHN, 2006, BBA-BIOMEMBRANES, V1758, P1408, DOI 10.1016/j.bbamem.2006.03.030
  18. Gallo RL, 1997, J BIOL CHEM, V272, P13088, DOI 10.1074/jbc.272.20.13088
  19. Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x
  20. Iimura M, 2005, J IMMUNOL, V174, P4901
  21. Jeng L, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-28
  22. Kingsley SMK, 2016, CURR INFECT DIS REP, V18, DOI 10.1007/s11908-016-0535-8
  23. LARRICK JW, 1995, INFECT IMMUN, V63, P1291
  24. Lipovsky MM, 1997, CLIN IMMUNOL IMMUNOP, V84, P208, DOI 10.1006/clin.1997.4381
  25. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  26. Martin L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00404
  27. Mookherjee N, 2007, EXPERT OPIN THER TAR, V11, P993, DOI 10.1517/14728222.11.8.993
  28. Munoz M, 2016, J CANCER, V7, P2341, DOI 10.7150/jca.16947
  29. Muro M, 1997, INFECT IMMUN, V65, P1147
  30. Nagaoka I, 2012, ISRN MICROBIOL, V2012
  31. Nakagawa Y, 2015, J IMMUNOL, V194, P1274, DOI 10.4049/jimmunol.1402388
  32. Niyonsaba F, 2002, IMMUNOLOGY, V106, P20, DOI 10.1046/j.1365-2567.2002.01398.x
  33. Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587
  34. Oren Z, 1999, BIOCHEM J, V341, P501, DOI 10.1042/0264-6021:3410501
  35. PETERSON PK, 1995, INFECT IMMUN, V63, P1598
  36. Ramanathan B, 2002, MICROBES INFECT, V4, P361, DOI 10.1016/S1286-4579(02)01549-6
  37. Ries M, 2013, J LEUKOCYTE BIOL, V94, P123, DOI 10.1189/jlb.0612278
  38. Salzer S, 2014, J DERMATOL SCI, V76, P173, DOI 10.1016/j.jdermsci.2014.09.002
  39. Thomassin Jenny-Lee, 2012, Gut Microbes, V3, P556, DOI 10.4161/gmic.21656
  40. Tjabringa GS, 2006, INT ARCH ALLERGY IMM, V140, P103, DOI 10.1159/000092305
  41. von Kockritz-Blickwede M, 2008, BLOOD, V111, P3070, DOI 10.1182/blood-2007-07-104018
  42. Wan M, 2014, J LEUKOCYTE BIOL, V95, P971, DOI 10.1189/jlb.0513304
  43. Wewers MD, 2009, PURINERG SIGNAL, V5, P189, DOI 10.1007/s11302-009-9131-9
  44. WICHTERMAN KA, 1980, J SURG RES, V29, P189, DOI 10.1016/0022-4804(80)90037-2
  45. Yin J, 2010, INVEST OPHTH VIS SCI, V51, P1891, DOI 10.1167/iovs.09-3904
  46. Zaiou M, 2002, J MOL MED-JMM, V80, P549, DOI 10.1007/s00109-002-0350-6

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Carregar mais